173 related articles for article (PubMed ID: 15206060)
21. Pharmacogenetic information derived from analysis of HLA alleles.
Gatanaga H; Honda H; Oka S
Pharmacogenomics; 2008 Feb; 9(2):207-14. PubMed ID: 18370849
[TBL] [Abstract][Full Text] [Related]
22. Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet?
Phillips EJ
Clin Infect Dis; 2006 Jul; 43(1):103-5. PubMed ID: 16758425
[No Abstract] [Full Text] [Related]
23. Use of patch testing for the diagnosis of abacavir-related hypersensitivity reaction in HIV patients.
Giorgini S; Martinelli C; Tognetti L; Carocci A; Giuntini R; Mastronardi V; Torricelli F; Leoncini F; Lotti T
Dermatol Ther; 2011; 24(6):591-4. PubMed ID: 22515676
[TBL] [Abstract][Full Text] [Related]
24. Human leukocyte antigen-associated drug hypersensitivity.
Illing PT; Vivian JP; Purcell AW; Rossjohn J; McCluskey J
Curr Opin Immunol; 2013 Feb; 25(1):81-9. PubMed ID: 23141566
[TBL] [Abstract][Full Text] [Related]
25. Drug hypersensitivity in HIV.
Phillips E; Mallal S
Curr Opin Allergy Clin Immunol; 2007 Aug; 7(4):324-30. PubMed ID: 17620824
[TBL] [Abstract][Full Text] [Related]
26. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.
Chui CK; Brumme ZL; Brumme CJ; Yip B; Phillips EJ; Montaner JS; Harrigan PR
Clin Infect Dis; 2007 Jun; 44(11):1503-8. PubMed ID: 17479950
[TBL] [Abstract][Full Text] [Related]
27. Parsonage-Turner syndrome: a rare case of abacavir hypersensitivity reaction in HIV-infected patients.
Bellagamba R; Tommasi C; De Marco M; Narciso P
J Infect; 2008 Jul; 57(1):88-90. PubMed ID: 18514915
[No Abstract] [Full Text] [Related]
28. Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR.
Dello Russo C; Lisi L; Lofaro A; Di Giambenedetto S; Federico B; Madeddu G; Salerno M; Mura MS; Pirazzoli A; de Luca A; Cauda R; Navarra P
Pharmacogenomics; 2011 Apr; 12(4):567-76. PubMed ID: 21521028
[TBL] [Abstract][Full Text] [Related]
29. HLA alleles and drug hypersensitivity reactions.
Profaizer T; Eckels D
Int J Immunogenet; 2012 Apr; 39(2):99-105. PubMed ID: 22136512
[TBL] [Abstract][Full Text] [Related]
30. Abacavir hypersensitivity reaction.
AIDS Patient Care STDS; 2002 May; 16(5):242. PubMed ID: 12058699
[No Abstract] [Full Text] [Related]
31. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study.
Rauch A; Nolan D; Martin A; McKinnon E; Almeida C; Mallal S
Clin Infect Dis; 2006 Jul; 43(1):99-102. PubMed ID: 16758424
[TBL] [Abstract][Full Text] [Related]
32. Will pharmacogenomic discoveries improve HIV therapeutics?
Haas DW
Top HIV Med; 2005; 13(3):90-5. PubMed ID: 16170225
[TBL] [Abstract][Full Text] [Related]
33. Association between abacavir exposure and increased risk for cardiovascular disease in patients with human immunodeficiency virus.
Schafer JJ; Short WR; Squires KE
Pharmacotherapy; 2010 Oct; 30(10):1072-83. PubMed ID: 20874044
[TBL] [Abstract][Full Text] [Related]
34. Abacavir-induced agranulocytosis in two Taiwanese patients tested HLA-B*5701-negative.
Chen SJ; Yang SP; Hung CC; Fung CP
AIDS; 2010 May; 24(8):1238-9. PubMed ID: 20421748
[No Abstract] [Full Text] [Related]
35. Large lymphadenopathies complicating the abacavir hypersensitivity reaction.
García JT; González PR; Hernández-Mora MG; Novoa SR; Quintana FB; Lahoz JG; Vázquez VS
AIDS; 2007 Oct; 21(16):2254-6. PubMed ID: 18090059
[No Abstract] [Full Text] [Related]
36. Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study.
Rauch A; Nolan D; Thurnheer C; Fux CA; Cavassini M; Chave JP; Opravil M; Phillips E; Mallal S; Furrer H;
Antivir Ther; 2008; 13(8):1019-28. PubMed ID: 19195327
[TBL] [Abstract][Full Text] [Related]
37. Sweet's syndrome following abacavir therapy.
Del Giudice P; Vandenbos F; Perrin C; Bernard E; Marq L; Dellamonica P
J Am Acad Dermatol; 2004 Sep; 51(3):474-5. PubMed ID: 15337997
[No Abstract] [Full Text] [Related]
38. 1592 (abacavir): do not rechallenge after hypersensitivity reaction.
James JS
AIDS Treat News; 1997 Dec; (No 285):1, 5. PubMed ID: 11364916
[TBL] [Abstract][Full Text] [Related]
39. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
40. [New fixed once daily combination as nucleoside backbone. Basis for long-term therapy success].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():66-8. PubMed ID: 16385881
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]